Bioethics News

Stanford Uses CRISPR to Correct Sickle Cell, Human Trials Planned

(Reuters) –  Scientists at Stanford University School of Medicine have used the CRISPR gene editing tool to repair the gene that causes sickle cell disease in stem cells from diseased patients, paving the way for a potential cure for the disease, which affects up to 5 million people globally.  “What we’ve finally shown is that we can do it. It’s not just on the chalkboard,” said Dr. Matthew Porteus, senior author of the study published in the journal Nature.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.